GSK plc’s 5-in-1 meningitis vaccine, Penmenvy, received a positive recommendation from the US CDC's Advisory Committee on Immunization Practices on April 16, 2025, to be used for individuals over 10 years. The vaccine simplifies dosing and aims to improve vaccination rates for preventing invasive meningococcal disease.